Tanzania - Tiếng Anh - Tanzania Medicinces & Medical Devices Authority

alkem laboratories limited, india - amoxicillin , clavulanate potassium for oral suspension - powder for oral suspension - 125/31

Tanzania - Tiếng Anh - Tanzania Medicinces & Medical Devices Authority

alkem laboratories limited, india - cefixime - powder for oral suspension - 50

Tanzania - Tiếng Anh - Tanzania Medicinces & Medical Devices Authority

alkem laboratories limited, india - cefixime - tablet - 200

Tanzania - Tiếng Anh - Tanzania Medicinces & Medical Devices Authority

alkem laboratories limited, india - amoxicillin trihydrate & potassium clavulanate - powder for injection - 1000

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 262.94 mg (equivalent: cefalexin, qty 250 mg) - capsule - excipient ingredients: lactose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; brilliant blue fcf; purified water; quinoline yellow; allura red ac; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 525.87 mg (equivalent: cefalexin, qty 500 mg) - capsule - excipient ingredients: lactose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; brilliant blue fcf; quinoline yellow; purified water; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: magnesium stearate; crospovidone; lactose monohydrate; meglumine; colloidal anhydrous silica; sodium hydroxide; povidone - telmisartan is indicated for:,treatment of hypertension ,prevention of cardiovascular morbidity and mortality in patients 55 years or older with,coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic,attack or high risk diabetes with evidence of end organ damage.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; crospovidone; povidone; sodium hydroxide; meglumine; colloidal anhydrous silica; magnesium stearate - telmisartan is indicated for:,treatment of hypertension ,prevention of cardiovascular morbidity and mortality in patients 55 years or older with,coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic,attack or high risk diabetes with evidence of end organ damage.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 172.704 mg (equivalent: quetiapine, qty 150 mg) - tablet, film coated - excipient ingredients: povidone; titanium dioxide; microcrystalline cellulose; lactose monohydrate; magnesium stearate; sodium starch glycollate type a; macrogol 400; iron oxide yellow; calcium hydrogen phosphate dihydrate; hypromellose - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 115.136 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: macrogol 4000; calcium hydrogen phosphate dihydrate; magnesium stearate; titanium dioxide; microcrystalline cellulose; lactose monohydrate; hypromellose; povidone; sodium starch glycollate type a; iron oxide yellow - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia